Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice.

MLA

Bonhomme-Faivre, Laurence, et al. “Recombinant Interleukin-2 Treatment Decreases P-Glycoprotein Activity and Paclitaxel Metabolism in Mice.” Anti-Cancer Drugs, vol. 13, no. 1, Jan. 2002, pp. 51–57. EBSCOhost, https://doi.org/10.1097/00001813-200201000-00006.

APA

Bonhomme-Faivre, L., Pelloquin, A., Tardivel, S., Urien, S., Mathieu, M.-C., Castagne, V., Lacour, B., & Farinotti, R. (2002). Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anti-Cancer Drugs, 13(1), 51–57. https://doi.org/10.1097/00001813-200201000-00006

Chicago

Bonhomme-Faivre, Laurence, Anne Pelloquin, Sylviane Tardivel, Saik Urien, Marie-Christine Mathieu, Vincent Castagne, Bernard Lacour, and Robert Farinotti. 2002. “Recombinant Interleukin-2 Treatment Decreases P-Glycoprotein Activity and Paclitaxel Metabolism in Mice.” Anti-Cancer Drugs 13 (1): 51–57. doi:10.1097/00001813-200201000-00006.